secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001551152-25-000023
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge
-------------------------------------------------------------------------

- Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.
- Q1 2025 adjusted diluted EPS guidance: $2.34-$2.38 (prior $2.47-$2.51).
- Full-year 2025 adjusted diluted EPS guidance: $11.99-$12.19 (from $12.12-$12.32).
- Revised guidance excludes AbbVie-Gubra GUB014295 licensing deal closed after Q1.
- Company does not forecast future IPR&D milestones due to uncertainty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/0001551152-25-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/abbv-20250403.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer